Department of Gastrointestinal Surgery, YIDU Central Hospital, Weifang, China.
Hongmei Sun and Mingying Zhang contributed equally to the paper.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820946018. doi: 10.1177/1533033820946018.
Lung cancer is the leading cause of cancer-related death, and adenocarcinoma is the most common type of lung cancer. Although emerging evidence implicates the role of several aldehyde dehydrogenases in cancer progression, the expression and clinical significance of aldehyde dehydrogenase 3B1 in lung adenocarcinoma has never been studied.
In our study, the expression of aldehyde dehydrogenase 3B1 in 250 cases of lung adenocarcinoma was detected with immunohistochemistry, and the patients were further divided into subgroups with different aldehyde dehydrogenase 3B1 expression. Using real-time polymerase chain reaction, we investigated the aldehyde dehydrogenase 3B1 messenger RNA in 20 lung adenocarcinoma and paired normal lung tissues. With the χ test, we evaluated the clinical significance of aldehyde dehydrogenase 3B1 by analyzing its correlation with the clinicopathological factors. Propensity score matching was performed to balance the baseline of cohort. With univariate and multivariate analyses, we screened the prognostic factors of lung adenocarcinoma and identified the independent prognostic factors before and after the propensity score matching.
Aldehyde dehydrogenase 3B1 expression was significantly associated with the sex and age of patients, tumor size, and histological grade. High expression of aldehyde dehydrogenase 3B1 predicted the poor prognosis ( = .003). Moreover, male patients ( = .020), large tumor size ( = .009), advanced T stage ( = .001), positive lymphatic invasion ( < .001), and advanced tumor-node-metastasis stage ( < .001) were all the prognostic factors for unfavorable outcome. Aldehyde dehydrogenase 3B1 was an independent prognostic biomarker of lung adenocarcinoma, indicating the poor prognosis. In addition, after balancing the baseline characteristics by propensity score matching, we also demonstrated that aldehyde dehydrogenase 3B1 was an independent prognostic biomarker of lung adenocarcinoma ( = .007).
Aldehyde dehydrogenase 3B1 was an independent prognostic biomarker of lung adenocarcinoma, indicating the unfavorable prognosis. Postoperative detection of aldehyde dehydrogenase 3B1 would help stratify the high-risk patients with lung adenocarcinoma and guide individual treatment.
肺癌是癌症相关死亡的主要原因，腺癌是最常见的肺癌类型。尽管有新的证据表明几种醛脱氢酶在癌症进展中起作用，但醛脱氢酶 3B1 在肺腺癌中的表达和临床意义从未被研究过。
在我们的研究中，用免疫组织化学检测了 250 例肺腺癌中醛脱氢酶 3B1 的表达，并根据醛脱氢酶 3B1 的不同表达将患者进一步分为亚组。用实时聚合酶链反应，我们检测了 20 例肺腺癌和配对正常肺组织中的醛脱氢酶 3B1 信使 RNA。用卡方检验，我们通过分析其与临床病理因素的相关性来评估醛脱氢酶 3B1 的临床意义。采用倾向评分匹配来平衡队列的基线。通过单因素和多因素分析，筛选肺腺癌的预后因素，并在倾向评分匹配前后确定独立的预后因素。
醛脱氢酶 3B1 的表达与患者的性别和年龄、肿瘤大小和组织学分级显著相关。醛脱氢酶 3B1 的高表达预示着预后不良（=.003）。此外，男性患者（=.020）、肿瘤体积大（=.009）、T 分期高（=.001）、阳性淋巴浸润（<.001）和肿瘤-淋巴结-转移分期高（<.001）都是不利结局的预后因素。醛脱氢酶 3B1 是肺腺癌的独立预后生物标志物，表明预后不良。此外，通过倾向评分匹配平衡基线特征后，我们还证明醛脱氢酶 3B1 是肺腺癌的独立预后生物标志物（=.007）。
醛脱氢酶 3B1 是肺腺癌的独立预后生物标志物，表明预后不良。术后检测醛脱氢酶 3B1 有助于对肺腺癌高危患者进行分层，并指导个体化治疗。
